Efficacy and Safety of G001 in Patients With Osteoarthritis (OA) of the Knee: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Efficacy and Safety of G001 in Patients With Osteoarthritis (OA) of the Knee (NCT05007808), a randomized phase 2 study. The primary outcome is Change From Baseline in WOMAC Pain Subscale Score at Week 4/EOT.

2. Clinical Question

3. Trial Design

This was a Phase 2, multicenter, randomized, parallel-group, vehicle-controlled study in patients with osteoarthritis of the knee. The registry lists triple masking and describes the study as double-blind. Randomization used a 1:1 allocation ratio at the Baseline/Flare Visit 1. The study compared G001 topical gel with matching vehicle topical gel, with both applied to the index knee at 4 grams four times a day during 4 weeks of treatment.

Each patient's participation was described as approximately 7 weeks: approximately 1 week of screening, 4 weeks of treatment, and 2 weeks of post-treatment follow-up. Before treatment, prior NSAID and/or acetaminophen use was discontinued to allow for washout and symptom flare. Patients recorded worst daily and nightly pain in a diary, as well as study drug applications and rescue medication use. Acetaminophen was allowed for breakthrough pain as rescue medication, subject to the restrictions described in the registry record around the Baseline Visit and post-baseline efficacy assessments.

Patients were instructed to return to the clinic 3 to 7 days after their last study drug application for Flare Visit 2, and within approximately 2 weeks after their last application for end-of-study evaluations. The primary endpoint was assessed at Week 4. The registry reports enrollment of 210 and a completed status, with the study start recorded as 2021-01-06 and primary completion as 2023-01-04.

The primary outcome analysis used the modified intent-to-treat population. That definition required randomization, at least 1 dose of study drug, and both baseline/Flare Visit 1 and Week 4/End-of-Treatment efficacy assessments. The registry record does not report the original sample-size justification or the trial's full statistical analysis plan.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Following screening, prior NSAID and/or acetaminophen use was discontinued to allow for washout (3 to 7 days) and symptom flare. Eligible patients with adequate OA pain in the index knee were randomly assigned to G001 or Vehicle in a 1:1 allocation ratio.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Modified intent-to-treat (mITT) population: All randomized patients who received at least 1 dose of study drug and provided both baseline/Flare Visit 1 (FV1) and Week 4/End-of-Treatment (EOT) efficacy assessments.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Change From Baseline in WOMAC Pain Subscale Score at Week 4/EOT, measured over Week 4.

The primary endpoint was change from baseline in the WOMAC Pain Subscale score at Week 4/End-of-Treatment. The registry describes the scale as a five-item measure with a score range of 0 to 20; higher scores indicate worse outcome. The endpoint therefore records change in a pain score over the treatment period, with a negative change indicating a lower score relative to baseline. The endpoint is reported as a least-squares mean, a model-based mean intended to express the group result under the analysis used.

Using a continuous score retains information about the size and direction of change rather than reducing each patient's result to a yes-or-no category. Comparing average changes between randomized groups addresses whether the observed change differed between the G001 and vehicle groups. It is important to distinguish a change within each group from a difference between groups: both groups can show improvement from baseline while the randomized comparison remains small.

The primary analysis population was the modified intent-to-treat population, comprising randomized patients who received at least 1 dose and had both baseline/Flare Visit 1 and Week 4/End-of-Treatment assessments. The registry record reports this population definition but does not report further detail about how missing outcome values were handled. As a general statistical point, the analysis population and missing-data method affect which observations contribute to an estimated endpoint and how broadly the result can be interpreted.

7. Results Posted in the Registry

• G001 Topical Gel: mean -5.40 versus -5.20 on control; difference -0.20 (95% CI -1.09 to 0.69), standardized effect d = -0.06; z-test p = 0.659.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Worst Daytime Pain Severity Scores (11-point Pain NRS), Based on Daily Diary Recordings

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • G001 Topical Gel: mean -2.10 versus -2.00 on control; difference -0.10 (95% CI -0.66 to 0.46), standardized effect d = -0.05; z-test p = 0.724.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between G001 Topical Gel and the control. The interval gives the range of effects that remain compatible with the data.

Worst Nighttime Pain Severity Score (11-point NRS), Based on Daily Diary Recordings

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • G001 Topical Gel: mean -2.10 versus -1.90 on control; difference -0.20 (95% CI -0.75 to 0.35), standardized effect d = -0.10; z-test p = 0.478.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between G001 Topical Gel and the control. The interval gives the range of effects that remain compatible with the data.

Change From Baseline in WOMAC Physical Function Subscale Score at Week 4/EOT

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard errors.
• Result:
  • G001 Topical Gel: mean -12.50 versus -10.40 on control; difference -2.10 (95% CI -5.05 to 0.85), standardized effect d = -0.19; z-test p = 0.163.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between G001 Topical Gel and the control. The interval gives the range of effects that remain compatible with the data.

The secondary outcome pattern is broadly aligned with the primary comparison: the displayed estimates do not establish a clear between-group difference, and the intervals for the selected comparisons include zero. The registry's secondary outcome list covers daytime and nighttime pain, percentage reductions from baseline, WOMAC physical function, total and stiffness scores, and assessments at different time points. It reports 15 secondary outcomes. The available secondary summaries should be read as supporting context rather than as independent confirmation of the primary result.

The selected results include diary-based pain scores and a WOMAC physical-function score. Across these comparisons, the estimates lean toward a greater reduction in score with G001, but uncertainty remains substantial relative to the estimated contrasts. This general pattern is consistent with the primary estimate being close to zero and imprecise. It does not establish a separate treatment effect on a secondary outcome or resolve the uncertainty in the primary outcome.

Multiplicity is an important consideration because testing many outcomes increases the opportunity for at least one apparently unusual result by chance. Unadjusted p-values do not account for that opportunity. The registry record does not report a multiplicity adjustment or a hierarchy for the secondary outcomes, so any isolated secondary finding would carry less weight than the prespecified primary comparison. Secondary endpoints can still help describe the range of outcomes examined and whether their directions are broadly consistent, but they should not be treated as a collection of confirmatory tests absent a reported plan.

The record does not give a complete inferential analysis for every listed secondary outcome in the details described. Conclusions should therefore be limited to the posted summaries and their uncertainty rather than generalized to all aspects of pain, function, or the overall treatment experience.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Worst Daytime Pain Severity Scores (11-point Pain NRS), Based on Daily Diary Recordings
• Worst Nighttime Pain Severity Score (11-point NRS), Based on Daily Diary Recordings
• Percent Reduction From Baseline in Worst Daytime Pain
• Percent Reduction From Baseline in Worst Nighttime Pain
• Change From Baseline in WOMAC Physical Function Subscale Score at Week 4/EOT
• Change From Baseline in WOMAC Total Score at Week 4/EOT
• Change From Baseline in WOMAC Stiffness Subscale Score at Week 4/EOT
• Change From Baseline in WOMAC Total and Subscale Scores at Week 2

9. Statistical Interpretation

10. Statistical Methods Explained

The primary outcome is continuous: each participant's WOMAC Pain Subscale score can take values on a scale rather than being classified into a binary outcome. The registry reports least-squares mean changes and a least-squares mean difference. The sponsor's reported comparison used a two-sided t-test and reported a 95% confidence interval and p-value. These summaries answer related but distinct questions: the estimated difference gives the direction and magnitude of the contrast, the interval describes its uncertainty, and the p-value measures how compatible the observed data are with a specified no-difference model.

What does the between-group estimate represent?

The primary arm summaries are -5.4 for G001 and -5.2 for vehicle. The reported least-squares mean difference is -0.19. It compares the groups' changes rather than asking whether either group changed from its own baseline. A negative difference indicates a lower change estimate for G001 relative to vehicle, given the ordering used for the contrast. The practical meaning depends on the scale and the uncertainty; the estimate alone should not be interpreted as a precise or definitive treatment effect.

The registry calls the arm estimates least-squares means and reports standard errors of 0.32 for both groups. A standard error describes the estimated precision of a mean, not the spread of individual participant scores. As a general statistical distinction, a standard deviation describes variability among observations, whereas a standard error describes uncertainty in an estimated mean. The posted results do not include arm-specific confidence limits for the primary outcome, but the sponsor reports an interval for the between-group difference.

How should the t-test and p-value be read?

A two-sided t-test evaluates departures in either direction from the no-difference value. The reported p-value is 0.674. In general, a p-value is calculated under a statistical model that assumes no group difference and describes how unusual results at least as incompatible with that model would be. It is not the probability that the null hypothesis is true, and it does not quantify the chance that G001 will help a patient. The posted p-value does not indicate a statistically clear difference in the primary comparison.

The recalculation uses the posted summary statistics to obtain an unadjusted comparison. Its estimate is -0.2, with an interval from -1.087 to 0.687 and p = 0.659. The sponsor's analysis reports -0.19, an interval from -1.081 to 0.701, and p = 0.674. Small differences between these sets of summaries can arise because a summary-statistic recalculation does not reproduce every detail of the trial analysis. The registry record does not report enough detail to reconstruct the sponsor's full modeling choices.

Why does the analysis population matter?

The primary population is defined as randomized patients who received at least 1 dose and posted both baseline/Flare Visit 1 and Week 4/End-of-Treatment efficacy assessments. This is a modified intent-to-treat definition, not a description of every randomized patient regardless of treatment exposure or outcome availability. Requiring measurements at both time points means the primary change analysis concerns participants meeting those criteria. The registry record does not report the number excluded from this population or the reasons for any exclusions.

As a general statistical matter, analyzing only participants with observed endpoint data can be affected if the availability of those data is related to outcomes or treatment. Methods such as imputation, likelihood-based approaches, or sensitivity analyses can address missingness under different assumptions, but the specific missing-data methods are not reported in the registry record. No method should be inferred from the endpoint summaries alone.

What does over-dispersion mean for these outcomes?

Over-dispersion occurs when variation in observed data is larger than a model assumes. It matters because an analysis that understates variability can report confidence intervals that are too narrow and p-values that are too small. This is a general concept, not a reported feature of this trial. The primary outcome is a continuous score and is analyzed through mean estimates and a t-test; the registry record does not report an over-dispersion assessment or a correction for it.

For continuous outcomes, uncertainty depends on the variability of scores and the amount of information available. The posted primary summaries include standard errors, and the comparison includes a confidence interval. Those statistics allow readers to assess precision without converting the continuous score into a threshold outcome. The record does not report a clinically important difference threshold, so statistical uncertainty should not be mistaken for a judgment about clinical importance.

What is the status of the statistical plan?

The record reports a Phase 2 study and the primary endpoint analysis, but the original sample-size justification, interim analysis plan, and complete prespecified statistical plan are not reported in the registry record. The posted planning illustrations are recalculations based on observed effects and stated assumptions, not evidence of the trial's original design rationale. The registry record also does not report how multiplicity across primary and secondary testing was addressed. These missing details matter when assessing whether analyses were planned before results were known and how confirmatory any secondary findings may be.

11. Confidence Intervals and Precision

The sponsor's primary comparison has a 95% confidence interval from -1.081 to 0.701 around the reported least-squares mean difference of -0.19. The interval includes zero, so the data are compatible with no difference between groups under the analysis. It also extends to negative and positive values, indicating uncertainty about the direction of the underlying contrast. The estimate itself is close to zero, but the interval is wide enough to include values on either side of that estimate.

A confidence interval is a range of values that, under the assumptions of the method, is designed to capture the true contrast at the stated confidence level over repeated studies. It is not a range containing a fixed probability that the true effect lies within it. Its width reflects precision: narrower intervals indicate more precise estimates, while wider intervals indicate greater uncertainty. Interpretation also depends on the scale and on whether a difference would be meaningful, and the registry record does not report a threshold for clinical importance.

The unadjusted recalculation gives a 95% interval from -1.087 to 0.687 around -0.2. It likewise spans zero and is close to the sponsor's interval. The two intervals are not identical, because the recalculation from posted summaries is not a reproduction of every aspect of the sponsor's analysis. The sponsor's reported interval is the trial's own reported result.

The primary confidence interval is more informative than the p-value alone because it communicates both direction and a range of effect sizes consistent with the analysis. It does not show that the groups are equivalent: an equivalence conclusion would require an appropriate design and a prespecified margin, neither of which is reported in the registry record. The posted precision supports a cautious reading rather than a definitive claim of equality or benefit.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The sample-size table and curve are planning illustrations calculated from observed effects, not the trial's original sample-size plan. For these continuous outcomes, the figures are participants per arm. The registry's general note distinguishes this from time-to-event planning, where a table would give the total number of events; the outcomes are not time-to-event outcomes.

The stated planning assumptions are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. Each scenario uses the stated fraction of the observed effect as the effect to detect. The original trial design assumptions and sample-size justification are not reported in the registry record. The displayed planning counts therefore answer a hypothetical design question under those assumptions, not what the investigators necessarily planned.

The 80% power column gives the estimated participants per arm for a hypothetical study designed to have an 80% chance of detecting the selected effect under the listed assumptions, if that effect were the true one and the model assumptions held. The 90% column expresses the corresponding planning target at 90% power. These are design probabilities, not guarantees that a future study will produce a particular result. This is not observed power.

Rows for planning for 100%, 75%, and 50% of the observed effect let readers see how the projected sample size changes as the assumed effect becomes smaller. Smaller effects need more participants to distinguish them from random variation at the same significance and power targets. The primary outcome's observed difference is very close to zero, so planning from that estimate produces very large illustrative counts. Such estimates are particularly sensitive to uncertainty in the observed effect and should not be treated as reliable forecasts of a definitive trial's needs. A sound design would ordinarily use a justified target effect and variance assumptions, which are not reported in the registry record.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, Δ is the difference in means to detect and σ is the common standard deviation.

Worked calculation for this trial

1. Observed difference Δ = -0.200; pooled standard deviation σ = 3.256.
2. n = 2 × (1.96 + 0.842)² × 3.256² / -0.200² = 4,159.4, rounded up to 4,160 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
delta <- -0.2                      # observed difference in means
sigma <- 3.25555675055705                     # pooled standard deviation
n_per_arm <- function(power, frac = 1) {
  ceiling(round(2 * (z_a + qnorm(power))^2 * sigma^2 / (delta * frac)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (t-based, so very slightly larger)
cat("power.t.test:", round(power.t.test(delta = delta, sd = sigma, power = 0.80)$n, 1), "\n")

# Simulation: exact two-sample t-test using simulated means and variances
set.seed(5007808)
n    <- n_per_arm(0.80)
reps <- 20000
m_diff <- rnorm(reps, delta, sigma * sqrt(2 / n))             # difference in sample means
s2     <- sigma^2 * rchisq(reps, 2 * (n - 1)) / (2 * (n - 1))   # pooled sample variance
tstat  <- m_diff / sqrt(s2 * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(tstat) > qt(0.975, 2 * (n - 1))), reps))

Output from running the code

100% of observed effect: n per arm = 4,160 (80% power), 5,569 (90% power)
 75% of observed effect: n per arm = 7,395 (80% power), 9,900 (90% power)
 50% of observed effect: n per arm = 16,638 (80% power), 22,273 (90% power)
power.t.test: 4160.3 
Simulated power at n = 4,160 per arm: 0.802 (20000 replicates)

The simulation draws many sets of group means and variances at the planned sample size and counts how often the two-sample t-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Analyses Reported by the Sponsor

The sponsor reports a two-sided t-test for the primary comparison, with a least-squares mean difference of -0.19, a 95% confidence interval from -1.081 to 0.701, and p = 0.674. The unadjusted recalculation from the posted arm summaries is -0.2, with a 95% interval from -1.087 to 0.687 and p = 0.659. The estimates and intervals are close, and both intervals include zero.

The recalculation is a simple comparison based on posted summary statistics. It is useful as a check on the broad scale and direction of the reported result, but it is not a substitute for the sponsor's analysis. The sponsor may have used analysis details that cannot be reconstructed from the summaries alone; the registry record does not describe every such detail. The sponsor's estimate should therefore be treated as the trial's own reported analysis, while the recalculation is an approximate unadjusted reading.

The difference between the p-values does not change the overall interpretation: neither reported result indicates a clear between-group difference on the primary outcome. The record does not flag a discrepancy between the sponsor's analysis and the recalculation. The sponsor's analysis remains the appropriate reference for the trial's reported inferential result.

15. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary endpoint and 15 secondary outcomes, with 23 outcome measures recorded overall. Testing multiple outcomes raises a multiplicity issue: if each comparison is interpreted as an independent opportunity to find a difference, the chance of at least one apparently notable result can increase. This is a general statistical concern, not evidence that a particular secondary result is false.

The registry record does not report whether the trial used a multiplicity adjustment, a testing hierarchy, or another procedure to control the interpretation of multiple outcomes. It also does not report a complete prespecified analysis plan. Consequently, the posted secondary comparisons should be treated as exploratory or descriptive unless a separate protocol or analysis document establishes a confirmatory strategy. The primary endpoint remains the clearest reference for the trial's stated main efficacy question.

The primary population is the modified intent-to-treat population: randomized patients who received at least 1 dose and had both baseline/Flare Visit 1 and Week 4/End-of-Treatment efficacy assessments. This definition makes clear which patients were eligible for the reported primary assessment, but the registry record does not report how many randomized patients did not meet the definition or why. It does not report the extent or pattern of missing data for the primary endpoint.

Missing-data handling is also not reported in the registry record. There is no reported description of imputation, assumptions about why data may be missing, or sensitivity analyses assessing those assumptions. As a general principle, complete-case analyses can be biased if participants with missing measurements differ systematically in outcome from those with measurements. That possibility cannot be evaluated from the posted population definition alone.

The original sample-size justification, interim analysis plan, and other details of the trial's statistical plan are not reported in the registry record. The planning illustrations based on observed effects are not a substitute for those original decisions. These omissions constrain assessment of how analyses were prespecified and how robust the reported conclusions are to alternative methods.

16. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: atrial fibrillation (1.0%).

The serious adverse event summaries list 0 affected participants among 105 at risk in the G001 group and 1 among 105 at risk in the vehicle group. The registry lists atrial fibrillation as a serious adverse event term at 1.0%. Deaths were reported as 0 in each group. These figures describe the recorded events and denominators; they do not establish that an event was caused by the study gel or that the groups differ in safety.

Other adverse events were reported for 10 of 105 participants at risk in the G001 group and 5 of 105 at risk in the vehicle group. These are counts in the registry's other-adverse-event category and should not be conflated with serious adverse events. The record does not provide details about event severity, timing, duration, relatedness assessments, or the complete event-term breakdown.

Safety summaries are descriptive and should be interpreted in light of the study's size, duration, and follow-up. A small number of recorded events cannot exclude uncommon or delayed events. The registry record does not report enough detail to make causal conclusions from these group counts, and they should be read separately from the efficacy comparison.

17. What the Result Does, and Does Not, Mean

The primary result describes the average Week 4 change in WOMAC Pain Subscale score in the modified intent-to-treat population. The G001 and vehicle group means were -5.4 and -5.2, respectively, and the sponsor's reported between-group estimate was -0.19. Its 95% confidence interval, -1.081 to 0.701, includes zero. The result therefore does not show a clear difference between groups on the primary endpoint, while remaining compatible with a range of underlying differences.

This is not a demonstration that the treatments are equivalent, because the registry does not report an equivalence design or a prespecified equivalence margin. It is also not proof that G001 has no effect. A nonsignificant comparison can reflect a small true difference, limited precision, or both. The registry reports a Phase 2 trial, and the primary estimate is uncertain; the data should not be converted into a categorical claim that G001 works or does not work.

Both groups' reported mean changes were negative, but within-group change does not isolate the effect of the active gel. The randomized, vehicle-controlled comparison is intended to distinguish the difference between the groups from change that may occur in both groups. The trial's posted primary contrast is small and imprecise, so the within-group reductions should not be attributed to G001 alone.

The results apply to the recorded population, endpoint, and time point. The primary analysis required treatment exposure and both baseline and Week 4 assessments. The treatment period was 4 weeks, with approximately 2 weeks of post-treatment follow-up described. These results alone do not establish longer-term effects, effects in people outside the study's eligibility criteria, or effects on outcomes not measured in the trial.

The posted safety counts are descriptive and do not establish causation. Missing-data methods, multiplicity procedures, and the original design rationale are not reported in the registry record. Those limits, together with the uncertainty in the primary estimate, call for restrained interpretation rather than a broad conclusion about benefit, harm, or equivalence.

18. Why This Trial Matters Statistically

This trial is statistically informative because it uses a randomized, vehicle-controlled comparison to separate the group contrast from changes that may occur during participation in either group. The primary endpoint is a continuous pain score, allowing the comparison to retain the direction and size of change rather than relying only on a categorical response. The reported least-squares mean difference and confidence interval make the uncertainty of the comparison visible.

The main statistical lesson is that changes within both groups can coexist with little separation between groups. The primary means changed in a negative direction, but the treatment contrast was close to zero and its interval included zero. Reading only the within-group changes would obscure the randomized comparison that addresses the trial's main question.

The record also illustrates why an estimate, an interval, and a p-value should be read together. The estimate conveys direction and scale, the confidence interval shows a range of uncertainty, and the p-value addresses compatibility with a no-difference model. None alone establishes clinical importance. The registry does not report a threshold for clinical importance, so statistical summaries cannot be translated into a judgment about meaningful benefit.

Finally, the record makes visible the distinction between a trial's own reported analysis and a summary-statistic recalculation. Their results are close, but only the sponsor's reported analysis reflects the trial's stated t-test. The registry's lack of detail on multiplicity, missing data, and original sample-size planning also shows why a result needs to be interpreted alongside its analysis plan, not just its headline estimate.

19. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The treatment period was 4 weeks, with post-treatment follow-up described as approximately 2 weeks. The primary endpoint therefore addresses a short-term assessment; the record does not establish persistence of outcomes beyond the recorded follow-up. The study was Phase 2, and the registry record does not report a longer-term efficacy assessment for the primary comparison.

The primary analysis population required at least 1 dose and both baseline and Week 4 efficacy assessments. The registry record does not state how many randomized patients were excluded from this analysis population, what the reasons were, or how missing measurements were handled. This limits assessment of whether the analyzed participants represent all randomized patients.

The registry reports a list of secondary outcomes but does not report a multiplicity plan in the record. The absence of that detail makes isolated secondary comparisons less suitable for confirmatory interpretation. The original sample-size justification and the trial's full statistical analysis plan are also not reported. The planning illustrations based on observed effects cannot fill that gap or establish what assumptions governed the original design.

The population was described as patients with symptomatic knee osteoarthritis who had adequate osteoarthritis pain in the index knee. Generalizability beyond the enrolled population cannot be determined from the reported summaries. The trial compared topical G001 with a matching vehicle, so results from this comparison do not directly address other treatments or comparisons.

For safety, the registry's event counts do not provide complete details about timing, severity, relatedness, or the full event profile. Small event counts and the study's limited duration constrain what can be inferred about uncommon or delayed events. These limitations do not invalidate the reported comparisons, but they define the scope of conclusions the registry record supports.

20. Related Tutorials

21. Related Statistical Calculators

22. Sources

• ClinicalTrials.gov: Efficacy and Safety of G001 in Patients With Osteoarthritis (OA) of the Knee — NCT05007808.
• Registry record last updated 2024-04-23; status last verified 2024-03.
• Results first posted 2024-04-23.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

23. Record Summary

The registry describes NCT05007808 as a completed Phase 2, multicenter, randomized, parallel-group, vehicle-controlled study of G001 topical gel in patients with osteoarthritis of the knee. G001 and matching vehicle were applied to the index knee at 4 grams four times a day over 4 weeks. The primary endpoint was change from baseline in WOMAC Pain Subscale score at Week 4/End-of-Treatment.

The sponsor reported a least-squares mean difference of -0.19, with a 95% confidence interval from -1.081 to 0.701 and p = 0.674. The interval includes zero, and the estimate is close to zero. The posted summaries do not establish a clear between-group difference on the primary endpoint.

The record reports secondary outcomes and adverse event summaries, but the multiplicity plan, missing-data methods, original sample-size justification, and full statistical analysis plan are not reported in the registry record. Interpretation is therefore best kept to the reported outcomes, population, and follow-up.